- $172.35m
- $167.26m
- $109.43m
Brief: OptimizeRx Reports Q4 And Full Year 2021 Financial Results
Optimizerx Corp Expected To Post Earnings Of 21 Cents A Share: Earnings Preview
Brief: Optimizerx Announces Preliminary Fourth Quarter 2021 Financial Results
Brief: Optimizerx Announces Preliminary Fourth Quarter 2021 Financial Results
Brief: OptimizeRx CEO Issues Open Letter To Shareholders Detailing The Completion Of Internal Management Changes
Optimizerx Corp Reports Results For The Quarter Ended In September: Earnings Summary
Brief: Optimizerx Reports Q3 Non-Gaap Earnings Per Share $0.09
Brief: Optimizerx And Demandbase Form Exclusive Account-Based-Experience (Abx) Partnership
Brief: OPTIMIZERx Posts Q2 EPS Of $0.02
Optimizerx Corp Reports Results For The Quarter Ended In June: Earnings Summary
Optimizerx Corp Expected To Post Earnings Of 7 Cents A Share: Earnings Preview
Brief: OptimizeRx Announces Agreement With A Top Pharmaceutical Manufacturer
Optimizerx Corp Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Optimizerx Reports First Quarter 2021 Financial Results
Optimizerx Corp Expected To Post Earnings Of 1 Cents A Share: Earnings Preview
Brief: Optimizerx Expands Omni-Channel Platform Reach At Point-Of-Care
U.S. RESEARCH ROUNDUP-IRhythm Technologies, Northwestern, Supernus Pharmaceuticals
Brief: Optimizerx Recurring Revenue Grows As It Secures 19 New Enterprise-Level Engagements In Q1 2021
Brief: OPTIMIZERx Reports Q4 2020 Rev Up 123% To Record $16.4 Mln